PharmaMar out-licenses Aplidin for Asian markets

2 February 2016

Spanish biotech firm PharmaMar (PHM: MC) today announced an agreement with Singapore-based Specialised Therapeutics Asia Pte (STA) to market its marine-based anti-tumor compound Aplidin (plitidepsin) for the treatment of hematological tumors in 12 Asian countries: Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Myanmar, Papua New Guinea, Philippines, Singapore, Thailand and Vietnam.

Aplidin, the second anti-tumor compound to be developed by PharmaMar from a marine organism, is currently undergoing development for the treatment of hematological tumors. A number of clinical trials are currently under way in relapsed/refractory multiple myeloma, such as the ADMYRE Phase III trial, as well as a Phase II trial in T-cell lymphoma. Plitidepsin has been granted orphan drug status by the regulatory agencies in Europe and the USA.

Terms of the deal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK